Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026

Karyopharm Therapeutics Inc.

2025-Q3 EPS reported -$10.93 vs consensus -$3.19 ▼ miss (-242.3%)

Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).
Net loss $33.1M ($3.82/sh) vs $32.1M ($3.85/sh); operating loss improved 42% to $15.2M.
Phase 3 SENTRY myelofibrosis trial enrollment complete (353 pts); top-line data due March 2026.
Reaffirms FY2025 total rev guidance $140M-$155M, XPOVIO rev $110M-$120M; lowers expense guide to $235M-$245M.
Cash $46.2M at Sep 30 (proforma ~$78M after Oct 8 financing); expects liquidity into Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.